Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.36 |
| ▸ | PGR | P06401 | 4/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327669 | 0.83 | NR3C2 (0.37) | ALDH1A1MAPTPDE3BPDE3ASMYD3 | |
| SCHEMBL8191716 | 0.76 | PDE3B (0.41) | KMT2AALDH1A1PDE3BPDE3ANR3C2 | |
| SCHEMBL13424831 | 0.76 | MMP12 (0.45) | MAPTPKMPDE3BPDE3ANR3C2 | |
| SCHEMBL7291865 | 0.76 | PDE3B (0.50) | GAAKMT2AALDH1A1MAPTPKM | |
| SCHEMBL20580495 | 0.76 | GAA (0.44) | GAAKMT2AALDH1A1MAPTPKM | |
| SCHEMBL7281256 | 0.76 | GAA (0.44) | GAAKMT2AALDH1A1MAPTPKM | |
| SCHEMBL5215313 | 0.76 | NR3C2 (0.37) | ALDH1A1MAPTPDE3BPDE3ANR3C2 | |
| SCHEMBL5257024 | 0.76 | GAA (0.53) | GAAKMT2AALDH1A1MAPTPKM | |
| SCHEMBL23590875 | 0.75 | NR3C2 (0.38) | ALDH1A1MAPTPKMPDE3BPDE3A | |
| SCHEMBL30183935 | 0.74 | PDE3B (0.36) | ALDH1A1MAPTPDE3BPDE3ASMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | GAA 3554/4885KMT2A 2934/4885ALDH1A1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.